Literature DB >> 7898487

Alterations in G-proteins in congestive heart failure in cardiomyopathic (UM-X7.1) hamsters.

R Sethi1, N Bector, N Takeda, M Nagano, G Jasmin, N S Dhalla.   

Abstract

In order to explain the attenuated sympathetic support during the development of heart failure, the status of beta-adrenergic mechanisms in the failing myocardium was assessed by employing cardiomyopathic hamsters (155-170 days old) at moderate degree of congestive heart failure. The norepinephrine turnover rate was increased but the norepinephrine content was decreased in cardiomyopathic hearts. The number and the affinity of beta receptors in the sarcolemmal preparations were not changed in these hearts at moderate stage of congestive heart failure. While the basal adenylyl cyclase activity was not altered in sarcolemma, the stimulation of enzyme activity by NaF, forskolin, Gpp(NH)p or epinephrine was depressed in hearts from these cardiomyopathic hamsters. Since G-proteins are involved in modifying the adenylyl cyclase activity, the functional and bioactivities as well as contents of both Gs and Gi proteins were determined in the cardiomyopathic heart sarcolemma. The functional stimulation of adenylyl cyclase by cholera toxin, which activates Gs proteins, was markedly depressed whereas that by Pertussis toxin, which inhibits Gi proteins, was markedly augmented in cardiomyopathic hearts. The cholera toxin and pertussis toxin catalyzed ADP-ribosylation was increased by 37 and 126%, respectively; this indicated increased bioactivities of both Gs and Gi proteins in experimental preparations. The immunoblot analysis suggested 74 and 124% increase in Gs and Gi contents in failing hearts, respectively. These results suggest that depressed adenylyl cyclase activation in cardiomyopathic hamsters may not only be due to increased content and bioactivity of Gi proteins but the functional uncoupling of Gs proteins from the adenylyl cyclase enzyme may also be involved at this stage of heart failure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7898487     DOI: 10.1007/bf00926754

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  28 in total

1.  Stimulatory guanine nucleotide-binding protein and adenylate cyclase activities in Bio 14.6 cardiomyopathic hamsters at the hypertrophic stage.

Authors:  T Ikegaya; A Kobayashi; R B Hong; H Masuda; M Kaneko; Y Noboru
Journal:  Mol Cell Biochem       Date:  1992-03-04       Impact factor: 3.396

Review 2.  Beta-adrenergic receptor regulation in the heart in pathophysiologic states: abnormal adrenergic responsiveness in cardiac disease.

Authors:  C J Homcy; S F Vatner; D E Vatner
Journal:  Annu Rev Physiol       Date:  1991       Impact factor: 19.318

3.  Antisera of designed specificity for subunits of guanine nucleotide-binding regulatory proteins.

Authors:  S M Mumby; R A Kahn; D R Manning; A G Gilman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

4.  Adenylate cyclase activities of the sarcotubular membranes of the genetically myopathic hamsters.

Authors:  N S Dhalla; P V Sulakhe
Journal:  Biochem Med       Date:  1974-04

5.  Beta-adrenergic receptor properties of canine myocardium: effects of chronic myocardial infarction.

Authors:  J S Karliner; M Stevens; M Grattan; W Woloszyn; N Honbo; J I Hoffman
Journal:  J Am Coll Cardiol       Date:  1986-08       Impact factor: 24.094

6.  Chronic heart failure in the guinea pig increases cardiac alpha 1- and beta-adrenoceptors.

Authors:  J S Karliner; P Barnes; M Brown; C Dollery
Journal:  Eur J Pharmacol       Date:  1980-10-03       Impact factor: 4.432

7.  Dysfunction of the beta- and alpha-adrenergic systems in a model of congestive heart failure. The pacing-overdrive dog.

Authors:  A Calderone; M Bouvier; K Li; C Juneau; J de Champlain; J L Rouleau
Journal:  Circ Res       Date:  1991-08       Impact factor: 17.367

8.  Characterization of adenylyl cyclase in heart sarcolemma in the absence or presence of alamethicin.

Authors:  R Sethi; K S Dhalla; K R Shah; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1993-02-17       Impact factor: 3.396

9.  Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart.

Authors:  A M Feldman; A E Cates; W B Veazey; R E Hershberger; M R Bristow; K L Baughman; W A Baumgartner; C Van Dop
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

10.  Beta-adrenoceptor and adenylate cyclase function in the infarct model of rat heart failure.

Authors:  E A Chasteney; C S Liang; W B Hood
Journal:  Proc Soc Exp Biol Med       Date:  1992-05
View more
  6 in total

1.  Alterations of cardiac beta-adrenoceptor mechanisms due to calcium depletion and repletion.

Authors:  Xi Wang; Jingwei Wang; Satoshi Takeda; Vijayan Elimban; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2002-03       Impact factor: 3.396

Review 2.  Regulation of G protein function: implications for heart disease.

Authors:  J T Meij
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

Review 3.  Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure.

Authors:  X Wang; N S Dhalla
Journal:  Mol Cell Biochem       Date:  2000-11       Impact factor: 3.396

4.  Early fetal like slow Na+ current in heart cells of cardiomyopathic hamster.

Authors:  D Jacques; G Bkaily; G Jasmin; D Ménard; L Proschek
Journal:  Mol Cell Biochem       Date:  1997-11       Impact factor: 3.396

5.  Beta-adrenoceptor mediated signal transduction in congestive heart failure in cardiomyopathic (UM-X7.1) hamsters.

Authors:  D Kaura; N Takeda; R Sethi; X Wang; M Nagano; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

6.  TNF-alpha-mediated signal transduction pathway is a major determinant of apoptosis in dilated cardiomyopathy.

Authors:  Samarjit Das; Andrea P Babick; Yan-Jun Xu; Nobuakira Takeda; Delfin Rodriguez-Levya; Naranjan S Dhalla
Journal:  J Cell Mol Med       Date:  2009-09-14       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.